natgillin/translations-raw huggingface dataset:
If you are injecting LITAK by yourself, you will be instructed how to prepare and to give the injection.
Če si LITAK injicirate sami, vas bodo poučili, kako pripraviti in dati injekcijo.
Detailed instructions for subcutaneous injection are provided at the end of this leaflet.
Podrobna navodila za subkutano injiciranje so na koncu teh navodil.
LITAK should not be mixed with other medicines.
LITAKA ne smemo mešati z drugimi zdravili.
In case you inject an incorrect dose or you miss an injection of a dose, please report this immediately to your doctor.
Če si injicirate nepravilni odmerek ali izpustite injiciranje odmerka, prosimo, da to nemudoma sporočite vašemu zdravniku.
Like all medicines, LITAK can have side effects.
Kot vsa zdravila ima lahko tudi LITAK neželene učinke.
Side effects may occur during or following treatment.
Neželeni učinki se lahko pojavijo med zdravljenjem ali po njem.
Your doctor will discuss the side effects of LITAK with you and will explain the risks and the benefits of your treatment.
Vaš zdravnik se bo z vami pogovoril o neželenih učinkih LITAKA in vam razložil tveganja in koristi vašega zdravljenja.
Possible side effects may include:
Možni neželeni učinki lahko vključujejo:
(Frequencies are defined as follows: very common (more than 1 out of 10 persons), common (more than 1 out of 100 persons and less than 1 out of 10 persons), uncommon (more than 1 out of 1,000 persons and less than 1 out of 100 persons), rare (more than 1 out of 10,000 persons and less than 1 out of 1,000 persons), very rare (less than 1 out of 10,000 persons including isolated reports)
(Pogostnosti so definirane kot sledi: zelo pogosti (pri več kot 1 od 10 oseb), pogosti (pri več kot 1 od 100 oseb in pri manj kot 1 od 10 oseb), občasni (pri več kot 1 od 1. 000 oseb in pri manj kot 1 od 100 oseb), redki (pri več kot 1 od 10. 000 oseb in pri manj kot 1 od 1. 000 oseb), zelo redki (pri manj kot 1 od 10. 000 oseb, vključujoč osamljena poročila)
• Blood and immune system disorders:
• Bolezni krvi in imunskega sistema:
These are very common side effects of treatment with LITAK due to its inhibition of production of blood cells in bone marrow.
To so zelo pogosti neželeni učinki zdravljenja z LITAKOM zaradi njegovega zaviranja izdelovanja krvničk v kostnem mozgu.
A lower number of certain white blood cells (neutrophils, platelets and lymphocytes) may be found in your blood.
V vaši krvi bodo lahko ugotovili nižjo koncentracijo določenih belih krvničk (nevtrofilcev, trombocitov in limfocitov).
Your blood may not contain enough red blood cells (anaemia).
V vaši krvi morda ne bo dovolj rdečih krvničk (anemija).
Your immune system may become impaired (immunosuppression).
Morda bo okvarjeno delovanje vašega imunskega sistema (imunosupresija).
This could cause fever (high body temperature) as you may be more likely to develop infections.
To lahko povzroči povišano telesno temperaturo, ker boste bolj dovzetni za razvoj okužb.
The lower number of platelets can cause unusual bleeding (for example nose or skin bleeds).
Nižja koncentracija trombocitov lahko povzroči neobičajno krvavitev (na primer, krvavitve iz nosu ali v koži).
Prematurely induced destruction of red blood cells.
Prezgodaj sproženo uničenje rdečih krvničk.
Rejection response to blood transfusions and harmful effects due to the destruction of the tumour.
Zavrnitveni odziv na transfuzije krvi in škodljivi učinki zaradi uničenja tumorja.
24 • Nervous system disorders:
• Bolezni živčevja:
Very common:
23 Zelo pogosti:
Headache, dizziness, drowsiness.
Glavobol, omotica, zaspanost.
Sleeplessness, anxiety.
Nespečnost, tesnoba.
Sleepiness, numbness and tingling of the skin, weakness/ feebleness, inactivity, disorder of peripheral nerves, confusion, impaired ability to coordinate movements.
Občasni: lenobnost, otopelost, mravljinčenje po koži, šibkost/ oslabelost, nedejavnost, motnje perifernih živcev, zmedenost, okvarjena sposobnost za koordinacijo gibov.
Depression, epileptic attack.
Depresija, epileptični napad.
• Eye problems:
• Očesne bolezni:
Eye inflammation (conjunctivitis).
Vnetje očesa (konjunktivitis).
Swelling of the eyelid.
Oteklina veke.
• Heart problems:
• Srčne bolezni:
Increased heart rate, heart murmur, low blood pressure, decreased blood supply to the heart muscle.
Povišana srčna frekvenca, šum na srcu, nizek krvni tlak, znižana oskrba srčne mišice s krvjo.
• Respiratory disorders:
• Bolezni dihal:
Abnormal breath sounds, abnormal chest sounds, cough.
Nenormalni dihalni zvoki, nenormalni zvoki nad prsnim košem, kašelj.
Shortness of breath, swelling (infiltrations) in lung tissue due to infection, inflammation of mouth and tongue.
Zadihanost, oteklina (infiltracije) v tkivu pljuč zaradi okužbe, vnetje ustne votline in jezika.
Sore throat.
Bolečine v grlu.
Blood clot in the lung (lung embolism).
Krvni strdek v pljučih (pljučna embolija).
• Gastrointestinal and liver side effects:
• Neželeni učinki v prebavilih in jetrih:
Feeling and being sick, vomiting, constipation and diarrhoea.
Slabost in bruhanje, zaprtje in driska.
Gastrointestinal pain and presence of excessive amount of gas in the stomach or bowels (flatulence), mostly mild increases in liver laboratory values (bilirubin, transaminases) which will return to normal values once treatment is over.
Bolečine v prebavilih in navzočnost čezmerne količine plinov v želodcu ali črevesju (flatulenca), večinoma blaga povišanja vrednosti laboratorijskih preiskav jetrnega delovanja (bilirubin, transaminaze), ki se bodo povrnila na normalne vrednosti po koncu zdravljenja.
Severely reduced liver function.
Hudo okvarjeno delovanje jeter.
Inflammation of the gallbladder.
Vnetje žolčnika.
• Kidney disorders:
• Bolezni ledvic:
Reduced kidney function.
Okvarjeno delovanje ledvic.
• Skin reactions:
• Kožne reakcije:
Skin eruption (rash), swelling, redness as well as soreness around the site of injection, sweating.
Kožne vzbrsti (izpuščaj), oteklina, rdečina in tudi bolečina okrog mesta injiciranja, znojenje.
Itching, itching skin eruption (urticaria) and skin pain.
Srbenje, srbeče kožne vzbrsti (koprivnica) in bolečine v koži.
Inflammation of a vein.
Vnetje vene.
Skin reactions are mostly mild to moderate and usually resolve within a few days.
Kožne reakcije so večinoma blage do zmerne in običajno izzvenijo v nekaj dnevih.
• General disorders:
• Splošne težave:
Tiredness, chills, decreased appetite.
Utrujenost, mrazenje, zmanjšan tek.
Swelling in tissues (oedema), not feeling well, pain (muscle pain, joint pain, and bone pain).
Otekline v tkivih (edem), slabo počutje, bolečine (bolečine v mišicah, sklepih ali kosteh).
Malnutrition.
Slaba prehranjenost.
Reduced function of organs due to high amounts of a specific substance produced by the body (a glycoprotein).
Zmanjšano delovanje organov zaradi velikih količin posebne snovi, ki jo izdeluje telo (glikoprotein).
• Repeated occurrence of malignant disease cannot be excluded.
• Ponovitve pojava maligne bolezni ne moremo izključiti.
You may experience one or several of these symptoms; be sure to inform your doctor if you do.
Izkusite lahko enega ali več od teh simptomov; poskrbite, da o tem obvestite svojega zdravnika.
STORING LITAK
SHRANJEVANJE ZDRAVILA LITAKA
Store at 2°C to 8°C (in a refrigerator).
24 Shranjujte pri temperaturi med 2 °C in 8 °C (v hladilniku).
Do not use LITAK after the expiry date stated on the vial label and the outer carton.
LITAKA ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na oznaki viale in škatlici.
INFORMATION ON HOW TO INJECT LITAK
INFORMACIJE O TEM, KAKO INJICIRATI ZDRAVILO LITAK
This section contains information on how to give an injection of LITAK.
To poglavje vsebuje podatke o tem, kako dati injekcijo LITAKA.
Syringes must be disposed in a puncture-proof container.
Brizge morate odlagati v vsebnik, odporen proti vbodom.
If you have any question with regard to giving the injection, please ask your doctor or nurse for help.
Če imate kakršnakoli vprašanja v zvezi z dajanjem injekcije, prosimo, vprašajte vašega zdravnika ali medicinsko sestro za pomoč.
How do I inject LITAK myself?
Kako si sam injiciram LITAK?
You will need to give yourself an injection into the tissue just under the skin.
Injekcijo si boste morali dati v tkivo tik pod kožo.
This is known as subcutaneous injection.
Temu pravimo subkutana injekcija.
Your doctor will tell you how much LITAK you need and how often and when you have to inject yourself.
Vaš zdravnik vam bo povedal, koliko LITAKA potrebujete in kako pogosto ter kdaj si ga morate injicirati.
Equipment needed
Potrebna oprema
To give yourself a subcutaneous injection, you will need:
Za dajanje podkožne injekcije sebi boste potrebovali:
• one vial of LITAK (or two vials if you need to inject more than 5 ml),
• eno vialo LITAKA (ali dve viali, če si morate injicirati več kot 5 ml),
• one sterile syringe (e. g.
• eno sterilno brizgo (npr.
• one sterile injection needle (e. g.
• eno sterilno injekcijsko iglo (npr.
• alcohol wipes,
• alkoholne blazinice,
• a puncture-proof container for safe disposal of the used syringe.
• vsebnik, odporen proti vbodom, za varno odlaganje uporabljene brizge.
What should I do before I give myself a subcutaneous injection of LITAK?
Kaj moram narediti, preden si podkožno injiciram LITAK?
Before injection, allow LITAK to warm up to room temperature.
Pred injekcijo pustite, da se LITAK ogreje na sobno temperaturo.
Before you inject LITAK, you must do the following:
Pred injiciranjem LITAKA morate narediti sledeče:
Remove the red protective cap from the LITAK vial.
Z viale LITAKA snemite rdeči zaščitni pokrovček.
26 3.
25 3.
Draw the correct volume of LITAK into the syringe by pulling back the plunger (your doctor will inform you how many ml of LITAK you need to inject).
Potegnite pravilno prostornino LITAKA v brizgo tako, da izvlečete bat (vaš zdravnik vam bo povedal, koliko ml LITAKA si morate injicirati).
What is Livensa used for?
Za kaj se uporablja zdravilo Livensa?
Livensa is used to treat women who have had their uterus (womb) and both ovaries removed, when they have a lack of sexual thoughts and sexual desire that is causing them distress.
Zdravilo Livensa se uporablja za zdravljenje žensk, ki so jim odstranili maternico in oba jajčnika, v primeru pomanjkanja spolnih misli in spolnega poželenja, zaradi česar so v osebni stiski.
The active substance in Livensa, testosterone, is a natural sex hormone produced in men and, to a lesser extent, in women.
Učinkovina v zdravilu Livensa, testosteron, je naravni spolni hormon, ki se tvori pri moških in v manjši meri pri ženskah.
Livensa releases testosterone through the skin into the bloodstream to produce testosterone levels that match the levels seen before removal of the uterus and ovaries.
Zdravilo Livensa sprosti testosteron skozi kožo v krvni obtok, s čimer se vzpostavi raven testosterona, ki ustreza ravni, izmerjeni pred odstranitvijo maternice in jajčnikov.
Because testosterone is a well-known active substance that is already used in other medicines, the company used data from the published literature as well as carrying out studies itself.
Glede na dejstvo, da je testosteron dobro znana učinkovina, ki se uporablja tudi v drugih zdravilih, je družba uporabila podatke iz objavljene literature, izvedla pa je tudi lastne študije.
The two main studies involved 1,095 women with an average age of 49 years who received Livensa for up to a year.
V dveh glavnih študijah je sodelovalo 1095 žensk s povprečno starostjo 49 let, ki so prejemale zdravilo Livensa v obdobju do enega leta.
Reproduction is authorised provided the source is acknowledged. satisfying sexual episodes in a four-week period.
Reproduction is authorised provided the source is acknowledged. beleženja števila zadovoljivih spolnih odnosov v štiritedenskem obdobju merili spolno zanimanje in spolne aktivnosti.
Livensa was more effective than placebo.
Zdravilo Livensa bilo učinkovitejše od placeba.
When the results of the two studies were looked at together, the women who used Livensa had an average of 1.07 more satisfying sexual episodes than the women who used placebo over a four-week period.
Analiza skupnih rezultatov obeh študij je pokazala, da so ženske, ki so uporabljale zdravilo Livensa, v štiritedenskem obdobju imele v povprečju za 1, 07 več zadovoljivih spolnih odnosov kot ženske, ki so uporabljale placebo.
In contrast, women who used placebo had around four episodes in a four- week period after six months.
V nasprotju s tem so ženske, ki so uporabljale placebo, imele po šestih mesecih okoli štiri spolne odnose v štiritedenskem obdobju.
The most common side effects with Livensa (seen in more than 1 patient in 10) are hirsutism (increased hair growth, especially on the chin and upper lip), and reactions at the site of application of the patch (redness and itching).
Najpogostejši neželeni učinki zdravila Livensa (opaženi pri več kot 1 od 10 bolnic) so hirsutizem (povečana rast dlak, zlasti na bradi in nad zgornjo ustnico) in reakcije na mestu namestitve obliža (rdečica in srbenje).
For the full list of all side effects reported with Livensa, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Livensa, glejte navodilo za uporabo.
Because testosterone is a male sex hormone, women who are taking Livensa should be monitored to see if they develop any ‘ androgenic’ side effects (development of male characteristics), such as hair growth on the face, deepening of the voice or hair loss.
Glede na to, da je testosteron moški spolni hormon, je potrebno ženske, ki jemljejo zdravilo Livensa, spremljati, da bi tako opazili, ali se pri njih pojavljajo „ androgeni “ neželeni učinki (pojavljanje moških značilnosti), kot so rast dlake na obrazu, znižanje glasu ali izpadanje las.
Livensa should not be used in people who may be hypersensitive (allergic) to testosterone or any of the other ingredients.
Zdravila Livensa ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) testosteron ali katero koli drugo sestavino zdravila.
It should also not be used in women who have, or have had breast cancer or another oestrogen-dependent cancer, or who have other conditions that mean that they cannot take oestrogen-containing medicines.
Ravno tako ga ne smejo uporabljati ženske, ki imajo ali so imele raka dojke ali katerega drugega od estrogena odvisnega raka oziroma katero drugo zdravstveno stanje, zaradi katerega ne smejo prejemati zdravil, ki vsebujejo estrogen.
Women using Livensa should also use oestrogens, but not of the type known as ‘ conjugated oestrogens ’ as this combination is not as effective.
Ženske, ki uporabljajo zdravilo Livensa, morajo jemati tudi estrogene, vendar ne tipa, znanega kot „ konjugirani estrogeni “, saj ta kombinacija ni učinkovita.
The Committee for Medicinal Products for Human Use (CHMP) decided that Livensa’ s benefits are greater than its risks for the treatment of hypoactive sexual desire disorder in bilaterally oophorectomised and hysterectomised women receiving concomitant oestrogen therapy.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Livensa večje od z njim povezanih tveganj pri zdravljenju hipoaktivnega spolnega poželenja pri ženskah z bilateralno ooforektomijo in histerektomijo, ki sočasno prejemajo zdravljenje z estrogenom.
The Committee recommended that Livensa be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Livensa odobri dovoljenje za promet.
Which measures are being taken to ensure the safe use of Livensa?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Livensa?
The company that makes Livensa will monitor some of the side effects of Livensa closely, such as androgenic side effects.
Družba, ki proizvaja zdravilo Livensa, bo skrbno spremljala nekatere neželene učinke zdravila Livensa, kot so npr. androgeni neželeni učinki.
The company will review all ongoing studies with Livensa to look at potential long-term risks including breast cancer, endometrial cancer (cancer of the lining of the womb) and side effects affecting the heart and blood vessels.
Družba bo pregledala vse potekajoče študije z zdravilom Livensa z namenom preučitve morebitnih dolgoročnih tveganj, ki vključujejo rak dojke, rak endometrija (rak maternične sluznice) in učinke, ki vplivajo na srce in ožilje.
The company will also provide an education plan for both doctors and patients.
Pripravila bo tudi izobraževalni načrt za zdravnike in bolnike.
The European Commission granted a marketing authorisation valid throughout the European Union for Livensa to Procter & Gamble Pharmaceuticals - Germany GmbH on 28 July 2006.
Evropska komisija je dovoljenje za promet z zdravilom Livensa, veljavno po vsej Evropski uniji, odobrila družbi Procter & Gamble Pharmaceuticals - Germany GmbH dne 28. julija 2006.
sachet (paper/ PE/ Alu/ ethylene methacrylic acid copolymer)
Zaščitna vrečka (papir/ polietilen/ aluminij/ kopolimer etilena in metakrilne kisline)
Livensa 300 micrograms/ 24 hours transdermal patch
Livensa 300 mikrogramov/ 24 ur transdermalni obliž
Concomitant estrogen treatment The appropriate use and restrictions associated with estrogen therapy should be considered before Livensa therapy is initiated and during routine re-evaluation of treatment.
Sočasno zdravljenje z estrogenom Pred zdravljenjem z zdravilom Livensa in med rutinskimi ponovnimi ocenitvami zdravljenja je treba upoštevati ustrezno uporabo in omejitve, povezane z zdravljenjem z estrogenom.
Continued use of Livensa is only recommended while concomitant use of estrogen is considered appropriate (i. e. the lowest effective dose for the shortest possible duration).
Neprekinjena uporaba zdravila Livensa se priporoča samo, dokler se ocenjuje, da je sočasna uporaba estrogena ustrezna (tj. najnižji možni učinkoviti odmerek v najkrajšem možnem času).
2 Patients treated with conjugated equine estrogen (CEE) are not recommended to use Livensa, as efficacy has not been demonstrated (see sections 4.4 and 5.1).
2 Bolnicam, ki prejemajo konjugirani konjski estrogen (CEE, conjugated equine estrogen), se uporaba zdravila Livensa ne priporoča, kajti učinkovitosti še niso dokazali (glejte poglavji 4. 4 in 5. 1).
Duration of treatment Livensa treatment response should be evaluated within 3-6 months of initiation, to determine if continued therapy is appropriate.
Trajanje zdravljenja Odziv na zdravljenje z zdravilom Livensa je treba oceniti v 3– 6 mesecih po začetku zdravljenja, da bi določili, ali je nadaljevanje zdravljenja primerno.
There is no relevant indication for use of Livensa in children and adolescents.
Ustreznih indikacij za uporabo zdravila Livensa pri otrocih in mladostnikih ni.
3 Livensa is recommended for use in surgically menopausal women up to the age of 60.
3 Zdravilo Livensa se priporoča pri ženskah po kirurški menopavzi, starih do 60 let.
Efficacy and safety of Livensa 300 micrograms in naturally menopausal women with HSDD on concomitant estrogen, with or without progestogen, have not been evaluated.
Učinkovitosti in varnosti zdravila Livensa 300 mikrogramov pri ženskah po naravni menopavzi s HSDD, ki sočasno uporabljajo estrogen, s progestagenom ali brez njega, niso ocenili.
Livensa 300 micrograms is not recommended in naturally menopausal women.
Uporaba zdravila Livensa 300 mikrogramov se ne priporoča ženskam po naravni menopavzi.
Therefore, Livensa should not be used in women on concomitant CEE (see sections 4.2 and 5.1).
Zato zdravila Livensa ne smejo uporabljati ženske, ki sočasno prejemajo CEE (glejte poglavji 4. 2 in 5. 1).
Livensa must not be used in women who are or may become pregnant or by breast-feeding women.
Zdravila Livensa ne smejo uporabljati nosečnice, ženske, ki lahko zanosijo, ali doječe ženske.
If an adverse reaction occurred at a higher frequency in the integrated phase III studies (Livensa patients n=1,498, placebo patients n=1,297), this frequency is reported in the table.
Če se je neželeni učinek pojavil pogosteje v integriranih študijah III. faze (bolnice, ki so prejemale zdravilo Livensa: n = 1. 498, bolnice, ki so prejemale placebo: n = 1. 297), je pogostnost navedena v tabeli.
In the combined study analysis at 24 weeks, the difference in the mean frequency of total satisfying episodes between Livensa and placebo was 1.07 per 4 weeks.
Pri analizi kombinirane študije po 24 tednih je bila razlika srednje vrednosti skupne pogostosti zadovoljivih epizod med zdravilom Livensa in placebom 1, 07 na 4 tedne.
In the combined phase III data, excluding patients taking oral CEE, in whom there was no significant improvement in sexual function, 50.7% of women (n=274) treated with Livensa and 29.4% of those treated with placebo (n=269) were responders with regard to total satisfying sexual activity (primary endpoint), when a responder was predefined as having an increase in the 4-week frequency of satisfying activities of > 1.
Oseba, ki se odziva na zdravljenje, je bila poprej opredeljena kot oseba, pri kateri je pogostost zadovoljivih aktivnosti v 4 tednih povečana za > 1.
Livensa is designed to systemically deliver 300 micrograms/ day.
Zdravilo Livensa je oblikovano tako, da sistemsko dovaja 300 mikrogramov/ dan.
Serum Concentrations of Testosterone and SHBG in Patients Receiving Livensa in Clinical Safety and Efficacy Studies Hormone
Koncentracije testosterona in SHBG v serumu pri bolnicah, ki so prejemale zdravilo Livensa v kliničnih študijah varnosti in učinkovitosti Hormon
Baseline Mean (SEM) N
Izhodiščna vrednost Srednja N vrednost (SEM)
Livensa 300 micrograms/ 24 hours transdermal patch Testosterone
Livensa 300 mikrogramov/ 24 ur transdermalni obliž Testosteron
Livensa 300 micrograms/ 24 hours transdermal patch Testosterone Transdermal use
Livensa 300 mikrogramov/ 24 ur transdermalni obliž Testosteron Transdermalna uporaba
What Livensa is and what it is used for 2.
Kaj je zdravilo Livensa in za kaj ga uporabljamo 2.
What you should consider before you use Livensa 3.
Kaj morate upoštevati, preden boste uporabili zdravilo Livensa 3.
How to use Livensa 4.
Kako uporabljati zdravilo Livensa 4.
How to store Livensa 6.
Shranjevanje zdravila Livensa 6.
Livensa is intended for use by women up to the age of 60 years who:  have a low sexual desire which is causing distress or concern, and  have had both of their ovaries removed, and  have had their womb removed (hysterectomy), and  are receiving estrogen therapy.
Zdravilo Livensa je namenjeno ženskam, starim do 60 let, ki:  imajo nizko spolno željo, ki povzroča stisko ali skrbi in  so jim odstranili oba jajčnika in  so jim odstranili maternico (histerektomija) in  prejemajo zdravljenje z estrogenom.
If you have not experienced a positive effect of Livensa within 3-6 months, you should inform your doctor, who will suggest that treatment be discontinued.
Če ugodnega učinka zdravila Livensa ne opazite v 3– 6 mesecih, morate obvestiti svojega zdravnika, ki vam bo predlagal, da zdravljenje prekinete.
WHAT YOU SHOULD CONSIDER BEFORE YOU USE LIVENSA
KAJ MORATE UPOŠTEVATI, PREDEN BOSTE UPORABILI ZDRAVILO LIVENSA
Do not use Livensa  if you are allergic (hypersensitive) to testosterone or any of the other ingredients of Livensa.  if you know that you have had in the past, currently have, or think that you might have, breast cancer or any other cancer which your doctor has described as being caused or stimulated by the female hormone estrogen, also called ‘ estrogen-dependent’ cancers.  if you have other conditions that your doctor may consider not appropriate for the use of estrogen and/ or testosterone.
Ne uporabljajte zdravila Livensa  če ste alergični na (preobčutljivi za) testosteron ali katerokoli sestavino zdravila Livensa;  če veste, da ste v preteklosti imeli, trenutno imate ali mislite, da bi lahko imeli rak dojke ali katerikoli drugi rak, za katerega zdravnik meni, da ga je povzročil ali spodbudil ženski hormon estrogen; tak rak se imenuje tudi "od estrogena odvisni rak";  če imate druge bolezni, zaradi katerih vaš zdravnik meni, da ne smete uporabljati estrogena in/ ali testosterona.